Fábio Trindade

Dr. Fábio Trindade

UnIC - Cardiovascular Research & Development Centre, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2014 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
PDF file
FTFábio Trindade
Fábio Trindade
FOFrank G. Oppenheim
Frank G. Oppenheim
EHEva J. Helmerhorst
Eva J. Helmerhorst
FAFrancisco Amado
Francisco Amado
Pedro GomesPedro Gomes
Pedro Gomes
Rui VitorinoRui Vitorino
Rui Vitorino

17 January 2017 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
PBPaulo Bastos
Paulo Bastos
FTFábio Trindade
Fábio Trindade
Joao Pinto da CostaJoao Pinto da Costa
Joao Pinto da Costa
RFRita Ferreira
Rita Ferreira
Rui VitorinoRui Vitorino
Rui Vitorino

18 January 2019 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
FTFábio Trindade
Fábio Trindade
Rui VitorinoRui Vitorino
Rui Vitorino
AMAdelino Leite Moreira
Adelino Leite Moreira
IFInês Falcão-Pires
Inês Falcão-Pires

9 March 2015 in Proteomics
Verified
Journal Article
Closed access
PDF file
PSPatrícia de Sousa‐Pereira
Patrícia de Sousa‐Pereira
MCMarta Cova
Marta Cova
JAJoana Abrantes
Joana Abrantes
RFRita Ferreira
Rita Ferreira
FTFábio Trindade
Fábio Trindade
Rui VitorinoRui Vitorino
Rui Vitorino

4 June 2024 in European Journal of Heart Failure
Verified
Journal Article
Closed access
IFInês Falcão-Pires
Inês Falcão-Pires
AFAna Filipa Ferreira
Ana Filipa Ferreira
FTFábio Trindade
Fábio Trindade
LBLuc Bertrand
Luc Bertrand
MCMichele Ciccarelli
Michele Ciccarelli
CTCarlo Gabriele Tocchetti
Carlo Gabriele Tocchetti
Cardiovascular disease (CVD) is the leading cause of morbimortality in Europe and worldwide. CVD imposes a heterogeneous spectrum of cardiac remodelling, depending on the insult nature, that is, pressure or volume overload, ischaemia, arrhythmias, infection, pathogenic gene variant, or cardiotoxicity. Moreover, the progression of CVD-induced remodelling is influenced by sex, age, genetic background and comorbidities, impacting patients' outcomes and prognosis. Cardiac reverse remodelling (RR) is defined as any normative improvement in cardiac geometry and function, driven by therapeutic interventions and rarely occurring spontaneously. While RR is the outcome desired for most CVD treatments, they often only slow/halt its progression or modify risk factors, calling for novel and more timely RR approaches. Interventions triggering RR depend on the myocardial insult and include drugs (renin–angiotensin–aldosterone system inhibitors, beta-blockers, diuretics and sodium–glucose cotransporter 2 inhibitors), devices (cardiac resynchronization therapy, ventricular assist devices), surgeries (valve replacement, coronary artery bypass graft), or physiological responses (deconditioning, postpartum). Subsequently, cardiac RR is inferred from the degree of normalization of left ventricular mass, ejection fraction and end-diastolic/end-systolic volumes, whose extent often correlates with patients' prognosis. However, strategies aimed at achieving sustained cardiac improvement, predictive models assessing the extent of RR, or even clinical endpoints that allow for distinguishing complete from incomplete RR or adverse remodelling objectively, remain limited and controversial. This scientific statement aims to define RR, clarify its underlying (patho)physiologic mechanisms and address (non)pharmacological options and promising strategies to promote RR, focusing on the left heart. We highlight the predictors of the extent of RR and review the prognostic significance/impact of incomplete RR/adverse remodelling. Lastly, we present an overview of RR animal models and potential future strategies under pre-clinical evaluation.

21 June 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
AMAna Merino-Ribas
Ana Merino-Ribas
Ricardo AraujoRicardo Araujo
Ricardo Araujo
LPLuciano Pereira
Luciano Pereira
Joana CamposJoana Campos
Joana Campos
LBLuisa Barreiros
Luisa Barreiros
Benedita Sampaio-MaiaBenedita Sampaio-Maia
Benedita Sampaio-Maia
Vascular calcification (VC) is a frequent condition in chronic kidney disease (CKD) and a well-established risk factor for the development of cardiovascular disease (CVD). Gut dysbiosis may contribute to CVD and inflammation in CKD patients. Nonetheless, the role of gut and blood microbiomes in CKD-associated VC remains unknown. Therefore, this pilot study aimed to explore the link between gut and blood microbiomes and VC in CKD patients on peritoneal dialysis (CKD-PD). Our results showed relative changes in specific taxa between CKD-PD patients with and without VC, namely Coprobacter, Coprococcus 3, Lactobacillus, and Eubacterium eligens group in the gut, and Cutibacterium, Pajaroellobacter, Devosia, Hyphomicrobium, and Pelomonas in the blood. An association between VC and all-cause mortality risk in CKD-PD patients was also observed, and patients with higher mortality risk corroborate the changes of Eubacterium eligens in the gut and Devosia genus in the blood. Although we did not find differences in uremic toxins, intestinal translocation markers, and inflammatory parameters among CKD-PD patients with and without VC, soluble CD14 (sCD14), a nonspecific marker of monocyte activation, positively correlated with VC severity. Therefore, gut Eubacterium eligens group, blood Devosia, and circulating sCD14 should be further explored as biomarkers for VC, CVD, and mortality risk in CKD.